NCT02223247View on ClinicalTrials.gov

A Phase 1, First-In-Human Study of Escalating Doses of Oral TVB-2640 in Patients With Solid Tumors

PHASE1CompletedINTERVENTIONAL
Enrollment

180

Participants

Timeline

Start Date

November 30, 2013

Primary Completion Date

June 30, 2017

Study Completion Date

June 30, 2017

Conditions
Solid Malignant Tumor
Interventions
DRUG

TVB-2640

Trial Locations (11)

34232

Sarasota

37203

Nashville

73104

Oklahoma City

75390

Dallas

78229

San Antonio

80218

Denver

85258

Scottsdale

Unknown

Charthouse Square, London

Manchester

West Smithfield, London

W1G 6AD

London

All Listed Sponsors
lead

Sagimet Biosciences Inc.

INDUSTRY

NCT02223247 - A Phase 1, First-In-Human Study of Escalating Doses of Oral TVB-2640 in Patients With Solid Tumors | Biotech Hunter | Biotech Hunter